The Bullous Pemphigoid Steroids and Tetracyclines Study
- Conditions
- Bullous pemphigoidSkin and Connective Tissue DiseasesPemphigoid
- Registration Number
- ISRCTN13704604
- Lead Sponsor
- niversity of Nottingham (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 256
1. Both males and females, aged at least 18 years old
2. Able to provide written informed consent
3. Clinical features consistent with bullous pemphigoid
4. Either a direct or indirect (serum) immuno-fluorescence (linear IgG/C3 at epidermal basement membrane zone) positive for bullous pemphigoid
5. At least three significant blisters spread over two or more body sites that have appeared in the week prior to study enrolment
6. Free of blisters and any treatment for previous episodes of bullous pemphigoid for at least one year
1. Received any of the study medications or other recognised systemic medications for the treatment of this episode of bullous pemphigoid prior to study entry. Prior topical treatment for this episode is permitted.
2. Recent administration of a live virus vaccine
3. Mainly or entirely mucosal pemphigoid
4. Known allergy to tetracyclines
5. Presence of any condition which precludes the use of either of the study drugs
6. Women of childbearing potential who are not taking adequate contraception or who are pregnant, plan to become pregnant during the study duration or lactating
7. Has active cancer (apart from basal cell carcinoma and Bowen's disease)
8. Has any other condition which would, in the Investigator's opinion, deem the patient unsuitable for participation in the study
9. Taking part in any other intervention study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method